During the corresponding time, Maravai Lifesciences Holdings Inc recorded a revenue increase by 8.53 % year on year, sequentially revenue fell by -21.7 %. While revenue at the Maravai Lifesciences Holdings Inc 's corporate clients
Maravai Lifesciences Holdings Inc's Comment on Sales, Marketing and Customers
The company serves biopharmaceutical companies, emerging biotech firms, life science research organizations, academic research institutions, and diagnostics companies. Its markets focus on biopharmaceutical development, providing products for therapeutic, vaccine, and diagnostic applications. The business operates through two segments: TriLink and Cygnus. TriLink offers nucleic acid products and services, including mRNA, oligonucleotides, CleanCap® mRNA capping technology, ModTail™ poly(A) tail modification technology, synthesis inputs, nucleoside triphosphates, specialty enzymes, and mRNA manufacturing services. TriLink supports therapeutic and vaccine programs, including cell and gene therapies (CGT), from preclinical development through clinical phases, supplying both research-grade and GMP materials. Cygnus provides biologics safety testing products and services, such as host cell protein ELISA kits, impurity detection assays, viral clearance prediction tools, ancillary reagents, and custom analytical services.
News about Maravai Lifesciences Holdings Inc Contracts
In an unfolding legal development, investors in Maravai Lifesciences Holdings, Inc. a prominent biotech firm, are being advised to take swift action regarding a significant securities class action lawsuit. According to a recent statement from the Rosen Law Firm, a leading global investor rights law firm, the deadline for interested parties to seek lead plaintiff status is swiftly approaching, set for May 5, 2025. This call to action is specifically aimed at those who purchased securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024, and February 24, 2025.The context of this lawsuit is underscored by Maravai Lifesciences Holdings significant financial challenges during the spe...
: In a dramatic turn of events, Maravai LifeSciences Holdings, Inc. finds itself at the center of a class action lawsuit following significant financial upheavals. With reported revenue plunges of over 70% year-over-year during the specified period, the company and several of its top executives face allegations of violations under the Securities Exchange Act of 1934. This article explores the intricacies of the lawsuit, the role of the lead plaintiff, and the broader implications for stakeholders within the pharmaceutical and life sciences sectors.The pharmaceutical industry, known for its resilience, is periodically shaken by events that spotlight the delicate balance between corporate governance and financ...
Maravai LifeSciences Strengthens its Portfolio with Officinae Bio Acquisition: A New Era for RNA and mRNA DevelopmentIn a significant move that underscores its commitment to advancing life sciences, Maravai LifeSciences, Inc. (NASDAQ: MRVI) has officially completed the acquisition of Officinae Bio’s DNA and RNA business. This strategic acquisition is set to harness the innovative power of Officinae Bio’s AI-enabled mRNA design platforms while leveraging the robust drug substance manufacturing capabilities of Maravai and its subsidiary, TriLink BioTechnologies. As the world moves toward a future dominated by mRNA-based therapeutics and vaccines, this merger positions Maravai at the forefront of a rapidly...
TriLink BioTechnologies and Johns Hopkins University Establish RNA Innovation Center to Propel Transformational Research and Therapeutic DevelopmentSAN DIEGO - TriLink BioTechnologies (TriLink), a leading global provider of life science reagents and services under Maravai LifeSciences (NASDAQ: MRVI), has joined forces with Johns Hopkins University to form a groundbreaking RNA Innovation Center aimed at expediting research in RNA therapeutics and discovery. The newly established center, housed within the Johns Hopkins Whiting School of Engineering, will leverage TriLink s cutting-edge RNA synthesis technology to drive research and the development of innovative therapeutics. TriLink s substantial investment in...
SAN DIEGO - TriLink BioTechnologies, a global provider of reagents and services for life sciences and a company of Maravai LifeSciences (NASDAQ: MRVI), has announced the inauguration of a new mRNA (messenger RNA) cGMP (current Good Manufacturing Practice) manufacturing plant. The inaugurated 32,000-square-foot facilities have been specifically designed for mRNA manufacturing. This new development aims to assist drug developers in the advanced stage, from phase 2 onwards up to commercialization. TriLink BioTechnologies is making significant strides in the bio-manufacturing industry with this significant expansion.However, the parent company, Maravai Lifesciences Holdings Inc., has been facing financial turbul...
In recent years, mRNA-based therapeutics have emerged as a transformative approach in the field of biopharmaceutics, offering promising opportunities for the treatment of various diseases. Among the key players driving this innovation is TriLink BioTechnologies, a leading provider of custom nucleic acid-based technologies and solutions for the global life sciences community. TriLink s innovative CleanCap technology has gained significant attention for its potential to enhance the effectiveness and safety of mRNA therapeutics.Facts:TriLink BioTechnologies, a subsidiary of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI), has been instrumental in advancing the field of mRNA therapeutics. Maravai Lifesciences H...
Maravai Lifesciences Holdings Inc’s Comment on Sales, Marketing and Customers
The company serves biopharmaceutical companies, emerging biotech firms, life science research organizations, academic research institutions, and diagnostics companies. Its markets focus on biopharmaceutical development, providing products for therapeutic, vaccine, and diagnostic applications. The business operates through two segments: TriLink and Cygnus. TriLink offers nucleic acid products and services, including mRNA, oligonucleotides, CleanCap® mRNA capping technology, ModTail™ poly(A) tail modification technology, synthesis inputs, nucleoside triphosphates, specialty enzymes, and mRNA manufacturing services. TriLink supports therapeutic and vaccine programs, including cell and gene therapies (CGT), from preclinical development through clinical phases, supplying both research-grade and GMP materials. Cygnus provides biologics safety testing products and services, such as host cell protein ELISA kits, impurity detection assays, viral clearance prediction tools, ancillary reagents, and custom analytical services.
Sources:
Maravai Lifesciences Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Maravai Lifesciences Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Maravai Lifesciences Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
159.68 %